吡柔比星与羟基喜树碱预防膀胱肿瘤复发疗效及安全性的Meta分析  

Pirarubicin versus Hydroxycamptothecine bladder irrigation in prevention of recurrence of bladder tumor： a meta - analysis

作　　者：肖腾飞[1] 刘修恒[1] 匡幼林[1] 翁小东[1] 陈胜[1] 

机构地区：[1]武汉大学人民医院泌尿外科,430060

出　　处：《临床外科杂志》2011年第9期624-626,共3页Journal of Clinical Surgery

摘　　要：目的评价吡柔比星与羟基喜树碱预防膀胱肿瘤复发的疗效和安全性。方法依据循证医学原则，用Cochrane系统评价方法，检索2000年至2011年期间Cochrane图书馆、PUBMED、CNKI、CBM、万方、重庆维普数据库等，纳入吡柔比星与羟基喜树碱预防膀胱肿瘤复发疗效和安全性的随机对照实验（RCT），采用RevMan5．0软件行Meta分析。结果纳入9个RCTS，共832例患者。根据Cochrane系统评价体系，结果质量均达B级。Meta分析结果为灌注吡柔比星组患者随访1年和2年膀胱肿瘤复发率比羟基喜树碱组低[（OR=0．58，P〈0．05），（OR=0．64，P〈0．05）]。灌注吡柔比星后出现膀胱刺激征和血尿与羟基喜树碱比较差异无统计学意义[（OR：0．97，P〉0．05），（OR=0．96，P〉0．05）]。结论膀胱肿瘤术后灌注吡柔比星预防肿瘤复发的效果优于羟基喜树碱。Objective To compare the efficacy and safety of Pirarubicin （THP）versus Hydroxycamptothecine （HCIrF） bladder irrigation in prevention of recurrence of bladder tumor. Methods Based on the principles of evidence - based medicine and Cochrane systematic review methods, the Cochrane library, PUBMED, CNKI,CBM,Wanfang Data, Chongqing - VIP database and so on were searched for RCTs on efficiency and safety of THP versus HCPT in prevention of recurrence of bladder tumor after transurethral resection, published between 2000 and 2011. After study data were retrieved, meta - analysis was performed using RevMan 5.0 software. Results A total of 9 RCTs （ 832 patients） were included, of which the result quality were defined as Grade B according to Cochrane criteria. Meta - analysis showed that the 1 - and 2 - year recurrence rates of bladder cancer in THP infusion patients （ OR = 0. 58, P 〈 0. 05 ） were lower than those in HCPT infusion patients （ OR = 0.64, P 〈 0.05 ）. The bladder irritation and hematuria after THP irrigation（ OR = 0.97, P 〉 0. 05 ） and HCPT （ OR =1. 18, P 〉 0.05 ） had not statistically significant difference. Conclusion Pirarubicin irrigation is more recommended for prevention of the recurrence of bladder tumor after transurethral resection because of its better efficacy.

关 键 词：膀胱肿瘤 吡柔比星 羟基喜树碱 META分析 

分 类 号：R699.5[医药卫生—泌尿科学]